REGENXBIO Webcast: Phase I/II AFFINITY DUCHENNE® Trial Interim Data
REGENXBIO Inc., a pioneering biotech firm focused on gene therapy, will conduct a live webcast to delve into the interim clinical findings from their Phase I/II AFFINITY DUCHENNE® study. This research is centered on RGX-202, an experimental treatment for Duchenne muscular dystrophy. Dr. Aravindhan Veerapandiyan, the principal investigator of the trial, will not only present the data but also engage in a Q&A session during the webcast. Interested parties can tune in through the Investors section of REGENXBIO's official website, where a recording of the event will be accessible for a month post-presentation.
Dr. Veerapandiyan is also scheduled to present the interim clinical data at the Muscular Dystrophy Association's Clinical & Scientific Conference the following day, March 6, 2024, at 12:00 p.m. EST. His presentation, titled "RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy: Interim clinical data," will be part of the Clinical Trial Updates session. As the Director of the Comprehensive Neuromuscular Program and Co-Director of the Muscular Dystrophy Association Care Center at Arkansas Children's Hospital, Dr. Veerapandiyan's expertise is integral to the development and understanding of RGX-202.
REGENXBIO, established in 2009, has been at the forefront of AAV Therapeutics, a novel class of medicines that utilize gene therapy to treat various diseases. The company's pipeline includes treatments for retinal diseases and rare conditions, such as RGX-202 for Duchenne muscular dystrophy and RGX-121 for MPS II. Their AAV Therapeutic platform has already been used to treat thousands, including those with spinal muscular atrophy through Novartis' ZOLGENSMA. These therapies are intended as single treatments, which could revolutionize healthcare delivery for millions.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
